Respiri Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
19.00
94.00
5.00
-
-
Cost of Goods Sold (COGS) incl. D&A
-
-
-
295.00
125.40
Gross Income
-
-
-
295.00
125.40
SG&A Expense
10,997.00
6,201.00
3,203.90
3,063.90
3,963.50
EBIT
11,222.60
6,323.20
4,795.10
-
4,089.00
Non Operating Income/Expense
661.80
826.30
105.30
2.90
4.90
Pretax Income
10,310.00
5,464.40
4,683.70
3,347.70
4,068.70
Income Tax
-
-
672.80
825.60
861.50
Consolidated Net Income
10,310.00
5,464.40
4,010.90
2,522.10
3,207.20
Net Income
10,310.00
5,464.40
4,010.90
2,522.10
3,207.20
Net Income After Extraordinaries
10,310.00
5,464.40
4,010.90
2,522.10
3,207.20
Net Income Available to Common
10,310.00
5,464.40
4,010.90
2,522.10
3,207.20
EPS (Basic)
0.04
0.02
0.01
0.01
0.01
Basic Shares Outstanding
269,373.50
287,516.50
298,893.10
432,717.50
441,492.80
EPS (Diluted)
0.04
0.02
0.01
0.01
0.01
Diluted Shares Outstanding
269,373.50
287,516.50
298,893.10
432,717.50
441,492.80
EBITDA
10,978.00
6,107.00
4,562.90
3,063.90
3,963.50
Other Operating Expense
-
-
1,363.90
-
-
Non-Operating Interest Income
250.80
32.50
6.10
14.10
15.40

About Respiri

View Profile
Address
446 Collins Street
Melbourne Victoria (VIC) 3000
Australia
Employees -
Website http://www.respiri.com.au
Updated 07/08/2019
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. Its proprietary apps, software, and devices will help people monitor the symptoms of their conditions, increase their awareness of risk of attack, adhere to their medication plans, improve outcomes, and reduce healthcare expenditures. It operates through the Australia and Israel segments.